Helen Branswell

At least one may have developed symptoms, sources say, but test results not yet available

Animal study suggests Merck's Ervebo, designed for another strain of the virus, may offer some protection

Exit of Jeffery Taubenberger, director of NIAID, would widen leadership vacuum at nation's top biomedical research agency

Bid to keep virus out may create risks for infected Americans and discourage volunteers

With no licensed vaccines available to protect against the Ebola virus currently spreading in the Democratic Republic of the Congo, efforts are underway to fast-track development of at least three vaccines. But even with infusions of cash to help fund the work, it is likely to be months before clinical trials of vaccines that specifically target the Bundibugyo ebolavirus can begin.

Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment.

The director-general of the World Health Organization is profoundly worried about the Ebola outbreak in the DRC, he told STAT in an interview.

UniQure will submit Huntington's therapy for approval, Eli Lilly buys 4E Therapeutics, and more biotech news

A panel of advisers to FDA gave its endorsement to a seasonal mRNA flu vaccine that was developed by Moderna and that earlier this year became the subject of controversy.

An NIH grant proposal poses new threats, more cases of a livestock disease in Europe, and more health news from Morning Rounds